Breaking: FTC Seeks More Info on Pfizer's Seagen Merger Plan
- July 15th, 2023
- 337 views
Seagen Inc. (Nasdaq: SGEN) and Pfizer Inc. (NYSE: PFE) have encountered a regulatory hurdle in their planned merger. According to a regulatory filing with the SEC, both companies received a Second Request from the Federal Trade Commission (FTC) on July 14, 2023, regarding additional information and documentary materials related to the merger. This request triggers an extension of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The companies aim to comply promptly and cooperate with the FTC to advance the review process.
Furthermore, the merger has also been referred to the European Commission (EC) for review under Article 4(5) of the EU Merger Regulation. The EC has accepted jurisdiction, making approval from the EC a crucial condition for the completion of the merger.
Despite the regulatory challenges, Seagen and Pfizer expect the merger to be finalized in late 2023 or early 2024, subject to meeting customary closing conditions and obtaining required regulatory approvals.
On Friday, $SGEN closed at $198.00 (+0.43%), and $PFE closed at $36.32 (+0.72%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Tags
Post Your Comments
Want To Find Some News?
Recent Posts
-
A Preview: Oracle, Franco-Nevada, and Asana Earnings Due
March 09th, 2025NVIDIA, Salesforce, and Agilent Technologies Earnings Loom: What to Expect
February 23rd, 2025Key Reports Ahead: KBR, Hims & Hers Health, and Cleveland-Cliffs Earnings Preview
February 23rd, 2025Earnings On Deck: What to Expect from Copart, Cheniere Energy, and Insulet
February 16th, 2025
Member Login